Do you suffer from Type 2 Diabetes, High Blood Pressure and Cardiovascular Disease?
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.
Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine.
Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo.
Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants’ health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants’ health and take note of any unwanted effects.
Would you like to take part in this research study?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow up of your condition to monitor the safety and effectiveness of the care you’ll receive. Study volunteers are an important part of moving medical care forward.
You may qualify to participate in this study if you:
- Are at least 18 years old at time of consent
- Provide signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
- Are a woman of childbearing potential (WOCBP): must be ready and able to use highly effective methods of birth control per ICH M3 (R2).
- Have a medical history of hypertension and on active pharmacological treatment
- Have a medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment
- Have an established cardiovascular (CV) disease and are on active pharmacological treatment
- Have at least one additional risk factor for developing heart failure (HF)
You may not qualify to participate in this study if you:
- Have a history of heart failure (HF) or hospitalization for HF or treatment of HF
- Experience atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening)
- Have any advanced untreated conduction disease or untreated clinically relevant ventricular arrhythmia at Visit 1 (screening)
- Have been treated with a Mineralocorticoid receptor antagonist (MRA)
- Have been treated with amiloride or other potassium-sparing diuretic
- Are receiving the following treatments at Visit 1 (screening) or requiring such treatment before Visit 2 (randomization), or planned during the trial:
- A direct renin inhibitor (e.g. aliskiren)
- More than one Angiotensin-converting enzyme inhibitor (ACEi) and/or Angiotensin receptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously
- Other aldosterone synthase inhibitors (e.g. baxdrostat)
- Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply
There are other eligibility requirements that the study doctor will review. Only the study doctor can determine whether you are eligible to participate in the study or not.
